Ensuring Success In Early Biopharmaceutical Formulation Development
Source: Catalent

Biopharmaceuticals tend to be highly unstable. A pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage, according to Yunsong (Frank) Li, director of process development at Catalent Biologics, in this interview.
VIEW THE Q&A!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
Catalent
This website uses cookies to ensure you get the best experience on our website. Learn more